CEP-32496, also known as RXDX-105, is primarily investigated for its potential in cancer therapy. It functions as a selective inhibitor of RET (Rearranged during Transfection) kinase, which is often implicated in various cancers, including non-small cell lung cancer (NSCLC) and thyroid cancer. By targeting RET mutations and fusions, CEP-32496 aims to disrupt the signaling pathways that drive tumor growth and progression. Its application is particularly significant in patients with RET-altered tumors, where it offers a targeted treatment approach, potentially improving outcomes compared to traditional chemotherapy. Additionally, its role in combination therapies is being explored to enhance efficacy and overcome resistance mechanisms in advanced cancers.